TrianglePembrolizumab (NCT07082439)
Pembrolizumab trial for Colorectal Adenocarcinoma Metastatic in the Liver (NCT07082439). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with liver-predominant metastatic colorectal cancer that is mismatch-repair proficient or not MSI-high. Prior fluoropyrimidine, oxaliplatin, irinotecan and VEGF-inhibitor treatment is required unless contraindicated; eligible wild-type tumors also require prior EGFR inhibition.
The idea: combine pembrolizumab and odetiglucan infusions every three weeks. Pembrolizumab blocks PD-1 immune suppression; odetiglucan stimulates innate immune cells. Researchers measure tumor responses and safety. Prior checkpoint therapy is excluded. Cancer cannot occupy more than half the liver.
This phase 2 study plans 27 patients. William Chapin leads Penn's single recruiting Philadelphia site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.